Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference
February 07 2023 - 08:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to develop and launch the first FDA-approved
ophthalmic formulation of bevacizumab for use in retinal
indications, today announced that Russ Trenary, President and Chief
Executive Officer of Outlook Therapeutics, will present at the SVB
Securities Global Biopharma Conference on Tuesday, February 14,
2023 at 4:20 PM ET.
In addition to the presentation, management will
be available to participate in virtual one-on-one meetings with
qualified members of the investor community who are registered to
attend the conference.
A live video webcast of the presentation will be
accessible on the Events page in the Investors section of the
Company’s website (outlooktherapeutics.com). The webcast replay
will be archived for 90 days following the event.
About Outlook Therapeutics,
Inc.Outlook Therapeutics is a biopharmaceutical company
working to develop and launch ONS-5010/ LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab for use in retinal indications, including wet AMD,
DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission
for ONS-5010 to treat wet AMD with a PDUFA goal date of August
29, 2023. The submission is supported by Outlook Therapeutics’ wet
AMD clinical program, which consists of three clinical trials:
NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic
bevacizumab is approved, Outlook Therapeutics expects to
commercialize it as the first and only FDA-approved ophthalmic
formulation of bevacizumab for use in treating retinal diseases
in the United States, United
Kingdom, Europe, Japan, and other markets. As part of the
Company’s multi-year commercial planning process, and in
anticipation of potential FDA approval in August
2023, Outlook Therapeutics and AmerisourceBergen have
entered into a strategic commercialization agreement to expand the
Company’s reach for connecting to retina specialists and their
patients. AmerisourceBergen will provide third-party logistics
(3PL) services and distribution, as well as pharmacovigilance
services in the United States. For more information, please
visit www.outlooktherapeutics.com.
CONTACTS:Media
Inquiries:Harriet UllmanVice President LaVoie Health
ScienceT: 617-669-3082hullman@lavoiehealthscience.com
Investor
Inquiries: Jenene
ThomasChief Executive OfficerJTC Team, LLCT:
833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Nov 2023 to Dec 2023
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Dec 2022 to Dec 2023